JP2003513012A - 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 - Google Patents

抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療

Info

Publication number
JP2003513012A
JP2003513012A JP2001514978A JP2001514978A JP2003513012A JP 2003513012 A JP2003513012 A JP 2003513012A JP 2001514978 A JP2001514978 A JP 2001514978A JP 2001514978 A JP2001514978 A JP 2001514978A JP 2003513012 A JP2003513012 A JP 2003513012A
Authority
JP
Japan
Prior art keywords
antibody
therapy
nhl
bone marrow
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001514978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003513012A5 (no
Inventor
ラステッター、ウィリアム、エイチ
Original Assignee
アイデック ファーマスーティカルズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイデック ファーマスーティカルズ コーポレイション filed Critical アイデック ファーマスーティカルズ コーポレイション
Publication of JP2003513012A publication Critical patent/JP2003513012A/ja
Publication of JP2003513012A5 publication Critical patent/JP2003513012A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
JP2001514978A 1999-08-11 2000-07-25 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 Pending JP2003513012A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11
US60/148,287 1999-08-11
PCT/US2000/040459 WO2001010462A1 (en) 1999-08-11 2000-07-25 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Publications (2)

Publication Number Publication Date
JP2003513012A true JP2003513012A (ja) 2003-04-08
JP2003513012A5 JP2003513012A5 (no) 2007-06-28

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001514978A Pending JP2003513012A (ja) 1999-08-11 2000-07-25 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療

Country Status (11)

Country Link
EP (1) EP1207906A4 (no)
JP (1) JP2003513012A (no)
CN (2) CN101259270A (no)
AU (1) AU784971B2 (no)
CA (1) CA2378646A1 (no)
HK (1) HK1048945A1 (no)
MX (1) MXPA02001398A (no)
MY (1) MY136635A (no)
NO (1) NO20020639L (no)
TW (1) TWI279233B (no)
WO (1) WO2001010462A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513390A (ja) * 2008-12-22 2012-06-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637160A3 (en) 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2003301445A1 (en) 2002-10-17 2004-05-04 Genmab A/S Human monoclonal antibodies against cd20
ES2633311T3 (es) 2002-12-16 2017-09-20 Genentech, Inc. Variantes de inmunoglobulina y usos de las mismas
PL1613350T3 (pl) 2003-04-09 2009-08-31 Genentech Inc Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
BRPI0411276A (pt) 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
ME03330B (me) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
KR20130099228A (ko) 2004-06-04 2013-09-05 제넨테크, 인크. 다발성 경화증의 치료 방법
CA2779559A1 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution Inc. Variant fc regions
PL1912675T3 (pl) 2005-07-25 2014-10-31 Emergent Product Dev Seattle Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
CN101267836A (zh) 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
NZ596865A (en) 2006-06-12 2013-07-26 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
SG10201913363VA (en) 2007-07-09 2020-03-30 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
KR20180105258A (ko) 2009-08-11 2018-09-27 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
CA2970738A1 (en) * 2015-01-23 2016-07-28 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
PL3303373T3 (pl) 2015-05-30 2020-09-21 Molecular Templates, Inc. Deimmunizowane rusztowania podjednostki a toksyny shiga oraz zawierające je cząsteczki nakierowane na komórki
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
KR20180054864A (ko) 2015-10-02 2018-05-24 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
BR112019004838A2 (pt) * 2016-09-16 2019-06-04 Nordic Nanovector Asa tratamento de linfoma não-hodgkin usando lilotomab e 177lu-lilotomab satetraxetan
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL174494B1 (pl) * 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5003003317, ＭＡＬＯＮＥＹ, ＯＮＣＯＬＯＧＹ, 199810, Ｖ１２Ｎ８, Ｐ６３−７６ *
JPN6010024381, Ｄ．Ｔ． ＮＧＵＹＥＮ ｅｔ ａｌ, Ｅｕｒ Ｊ Ｈａｅｍａｔｏｌ, 1999, Ｖ６２, Ｐ７６−８２ *
JPN6010024383, Ｓｕｓａｎ Ｊ． ＫＮＯＸ ｅｔ ａｌ, Ｃｌｉｎｉｃａｌ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 1996, Ｖ２, ｐ４５７−４７０ *
JPN7010001364, Ｗｈｉｔｅ ｅｔ ａｌ．, Ａｎｎａｌｓ ｏｆ Ｏｎｃｏｌｏｇｙ, 199903, Ｖｏｌ．１０， Ｓｕｐｐｌｅ．３, ｐ．６４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513390A (ja) * 2008-12-22 2012-06-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用

Also Published As

Publication number Publication date
WO2001010462A1 (en) 2001-02-15
CN1373671A (zh) 2002-10-09
MY136635A (en) 2008-11-28
AU7626000A (en) 2001-03-05
EP1207906A1 (en) 2002-05-29
NO20020639D0 (no) 2002-02-08
MXPA02001398A (es) 2002-08-12
AU784971B2 (en) 2006-08-10
CN100389825C (zh) 2008-05-28
CA2378646A1 (en) 2001-02-15
TWI279233B (en) 2007-04-21
NO20020639L (no) 2002-04-11
HK1048945A1 (en) 2003-04-25
EP1207906A4 (en) 2005-07-06
CN101259270A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
JP2003513012A (ja) 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
JP6253842B2 (ja) 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
JP2003513012A5 (no)
JP2003506413A (ja) 中間および高グレードの非ホジキンリンパ腫の抗−ｃｄ２０抗体による治療
Morschhauser et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma
Casacó et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma
JP2002529429A (ja) Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。
JP2003506414A (ja) 放射性免疫療法に先立つ血液学的毒性測定のための新規な臨床検査指標
BG62386B1 (bg) Метод за лечение на в-клетъчна лимфома
CN110536905A (zh) 用于治疗肺癌的抗pd-1抗体
KR20000070989A (ko) 임파구계 종양의 치료제
Lin Internal radiation therapy: a neglected aspect of nuclear medicine in the molecular era
Borghaei et al. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
Kuzel et al. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1
Li et al. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin
JP2003520250A (ja) 一部の癌の治療における抗フェリチンモノクローナル抗体の使用
Kalofonos et al. Antibody‐guided diagnosis and therapy of malignant lesions
Garkavij et al. Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F (ab') 2 in patients with MUC1-positive non-small cell lung cancer
TWI280137B (en) Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
ZA200704642B (en) Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
CN115611981A (zh) 抗pd-1抗体在治疗外周t细胞淋巴瘤中的应用
Weller et al. Eosinophils from patients with blood eosinophilia express
NZ722296B2 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101207